Publications by authors named "B De Win"
Article Synopsis
- Cabotegravir + rilpivirine is the first long-acting HIV treatment approved for intramuscular administration, typically in the gluteal area, but the lateral thigh is being explored as an alternative injection site.
- A study assessed the safety and pharmacokinetics of this treatment in healthy adults after they received initial oral doses followed by thigh injections, with evaluations continuing for 52 weeks post-injection.
- Results showed that thigh injections had similar tolerability and effectiveness compared to gluteal injections, with the most common side effects being mild pain and swelling at the injection site.
Associations of COVID-19 lockdown with gestational length and preterm birth in China.
BMC Pregnancy Childbirth
November 2021
Background: The effects of COVID-19 lockdown measures on maternal and fetal health remain unclear. We examined the associations of COVID-19 lockdown with gestational length and preterm birth (PTB) in a Chinese population.
Methods: We obtained medical records of 595,396 singleton live infants born between 2015 and 2020 in 5 cities in Guangdong Province, South China.
Background: Bupropion hydrochloride (Zyban) is an effective aid to smoking cessation; however, its use has previously been associated with neuropsychiatric adverse events. Here we report results of the patient Knowledge, Attitudes, and Behavior survey that forms part of the Year 7 Risk Evaluation and Mitigation Strategy (REMS) assessment for Zyban.
Objective: Assess participants' understanding of the neuropsychiatric risks associated with branded bupropion hydrochloride products that are used for smoking cessation, as described in the Medication Guides.
Background: Some observational studies and randomized controlled trials (RCTs) have suggested an association between abacavir (ABC) use and myocardial infarction (MI), whereas others have not.
Methods: This pooled analysis of 66 phase II-IV RCTs estimates exposure-adjusted incidence rates (IRs) and relative rates (RRs) of MI and cardiovascular events (CVEs) in participants receiving ABC- and non-ABC-containing combination antiretroviral therapy (cART). The primary analysis of MI included ABC-randomized trials with ≥48-week follow-up.
Article Synopsis
- This text indicates that there is a correction to the original article associated with the DOI: 10.1038/npp.2016.60.
- It highlights the importance of ensuring that published research is accurate and reliable.
- Readers are advised to refer to the corrected version for the most up-to-date information.